Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.74 |
| ▸ | MAPT | P10636 | 4/20 | 0.71 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.71 |
| ▸ | ABCG2 | Q9UNQ0 | 9/20 | 0.70 |
| ▸ | ABCB1 | P08183 | 6/20 | 0.70 |
| ▸ | TP53 | P04637 | 3/20 | 0.69 |
| ▸ | POLB | P06746 | 1/20 | 0.63 |
| ▸ | KIF11 | P52732 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14627230 | 0.93 | ABCG2 (0.70) | LMNAMAPTNPSR1ABCG2ABCB1 | |
| SCHEMBL998412 | 0.90 | MAPT (0.64) | LMNAMAPTNPSR1ABCG2ABCB1 | |
| SCHEMBL764085 | 0.90 | MAPT (0.86) | LMNAMAPTNPSR1ABCG2ABCB1 | |
| SCHEMBL9929250 | 0.86 | POLB (0.66) | LMNAMAPTNPSR1ABCG2ABCB1 | |
| SCHEMBL9928894 | 0.85 | PDE5A (0.67) | LMNAMAPTNPSR1TP53 | |
| SCHEMBL9928672 | 0.84 | ABCG2 (0.67) | LMNAABCG2ABCB1TP53POLB | |
| SCHEMBL8939319 | 0.83 | KIF11 (0.79) | LMNAABCG2ABCB1TP53KIF11 | |
| SCHEMBL2727340 | 0.83 | MAPT (0.67) | LMNAMAPTNPSR1ABCG2ABCB1 | |
| SCHEMBL9928863 | 0.83 | ABCG2 (0.71) | LMNAMAPTABCG2ABCB1POLB | |
| SCHEMBL3712664 | 0.82 | ABCG2 (1.00) | LMNAABCG2ABCB1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240043422-A1 | METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS | PTC THERAPEUTICS, INC. (US) | 2024-02-08 | — | — | US | disclosed |
| US-11613538-B2 | Method of inhibiting or reducing a viral infection | PTC THERAPEUTICS, INC. (US) | 2023-03-28 | — | — | US | disclosed |
| EP-2434891-B9 | METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS | PTC THERAPEUTICS INC (US) | 2021-05-05 | — | — | EP | disclosed |
| US-20200317668-A1 | METHOD OF INHIBITING OR REDUCING A CORONAVIRIDAE VIRUS INFECTION | PTC THERAPEUTICS, INC. | 2020-10-08 | — | — | US | disclosed |
| EP-3718405-A1 | METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS | PTC Therapeutics, Inc. (US) | 2020-10-07 | — | — | EP | disclosed |
| EP-2434891-B1 | METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS | PTC THERAPEUTICS INC (US) | 2020-07-22 | — | — | EP | disclosed |
| US-20160340354-A1 | METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS | PTC THERAPEUTICS, INC. | 2016-11-24 | — | — | US | disclosed |
| US-9351964-B2 | Methods for treating cancer and non-neoplastic conditions | PTC THERAPEUTICS, INC. (US) | 2016-05-31 | — | — | US | disclosed |
| US-8703726-B2 | Methods for treating prostate conditions | PTC THERAPEUTICS, INC. (US) | 2014-04-22 | — | — | US | disclosed |
| US-8697662-B2 | Methods for treating Kaposi sarcoma | PTC THERAPEUTICS, INC. (US) | 2014-04-15 | — | — | US | disclosed |
| US-20130171103-A1 | METHODS FOR TREATING VIRAL CONDITIONS | PTC THERAPEUTICS, INC. (US) | 2013-07-04 | — | — | US | disclosed |
| US-20120202763-A1 | METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS | PTC THERAPEUTICS, INC (US) | 2012-08-09 | — | — | US | disclosed |
| US-20120202801-A1 | METHODS FOR TREATING BREAST CANCER | PTC THERAPEUTICS, INC. | 2012-08-09 | — | — | US | disclosed |
| US-20120178707-A1 | METHODS FOR TREATING PROSTRATE CONDITIONS | PTC THERAPEUTICS, INC. | 2012-07-12 | — | — | US | disclosed |
| US-20120157400-A1 | METHODS FOR TREATING KAPOSI SARCOMA | PTC THERAPEUTICS, INC. | 2012-06-21 | — | — | US | disclosed |
| US-20120157401-A1 | METHODS FOR TREATING NEUROFIBROMATOSIS | PTC THERAPEUTICS, INC. | 2012-06-21 | — | — | US | disclosed |
| US-20120157402-A1 | METHODS FOR TREATING BRAIN TUMORS | PTC THERAPEUTICS, INC. | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157402-A1 | METHODS FOR TREATING BRAIN TUMORS | HDGF, VEGFA, FLT4 | LMNA 3379/4885MAPT 1046/4885NPSR1 588/4885 |
| US-20240043422-A1 | METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS | HDGF, POLRMT, VEGFA | LMNA 1839/4885MAPT 3300/4885NPSR1 4114/4885 |
| US-20160340354-A1 | METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS | HDGF, POLRMT, VEGFA | LMNA 1803/4885MAPT 3328/4885NPSR1 4085/4885 |
| US-20120202763-A1 | METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS | HDGF, POLRMT, VEGFA | LMNA 1803/4885MAPT 3328/4885NPSR1 4085/4885 |
| US-20200317668-A1 | METHOD OF INHIBITING OR REDUCING A CORONAVIRIDAE VIRUS INFECTION | SARS1, POLRMT, EIF2AK2 | LMNA 2784/4885MAPT 2964/4885NPSR1 3542/4885 |
| US-20120157401-A1 | METHODS FOR TREATING NEUROFIBROMATOSIS | VHL, NGF, VEGFA | LMNA 1622/4885MAPT 3613/4885NPSR1 761/4885 |
| US-20130171103-A1 | METHODS FOR TREATING VIRAL CONDITIONS | EIF2AK2, POLRMT, POLM | LMNA 1455/4885MAPT 2440/4885NPSR1 4203/4885 |
| US-11613538-B2 | Method of inhibiting or reducing a viral infection | SARS1, EIF2AK2, POLRMT | LMNA 2454/4885MAPT 2901/4885NPSR1 3558/4885 |
| US-20120157400-A1 | METHODS FOR TREATING KAPOSI SARCOMA | HDGF, HIF1AN, VEGFA | LMNA 1893/4885MAPT 3684/4885NPSR1 3288/4885 |
| US-20120202801-A1 | METHODS FOR TREATING BREAST CANCER | VEGFA, FLT4, FLT1 | LMNA 3985/4885MAPT 3448/4885NPSR1 2166/4885 |
| US-20120178707-A1 | METHODS FOR TREATING PROSTRATE CONDITIONS | ACP3, BPHL, PTGFR | LMNA 2939/4885MAPT 1384/4885NPSR1 233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.